Ewing sarcoma is a rare and aggressive form of bone cancer that primarily affects children, teenagers, and young adults. It can be treated successfully if the cancer is localised to one part of the body, but if it spreads to multiple sites in the body (has metastasised), or returns after completed treatment (relapses), or does not respond to treatment (is refractory), the chances of curing Ewing sarcoma are much reduced. Ewing sarcoma is caused by a very specific change in the DNA of cells, resulting in the occurrence of so-called fusion proteins that only exist in the tumour cells, effectively turning healthy cells into cancer cells.

Having a drug that effectively attacks this fusion protein might destroy the Ewing sarcoma cells. However, to date, no such drugs have been developed, therefore, new approaches are needed to tackle the fusion protein.

Recent research by Dr Herold's group has shown that using a combination of two established chemotherapy drugs can reduce the presence of the fusion protein, killing EWS cells. These drugs are called cytarabine and gemcitabine and encouragingly, are already approved for use in patients, which means we already know how safe they are.

Cytarabine has been shown to effectively attack the fusion protein, but when used in isolation, its effectiveness is limited / stopped due to a protein named SAMHD1 which is also present in the cancer cells. SAMHD1 inactivates the active form of cytarabine, thus protecting the fusion protein from destruction. The group discovered that in the laboratory, gemcitabine inhibits the activity of SAMHD1, allowing cytarabine to work.

What are the aims of this research project?

The research hopes to demonstrate that using combinations of gemcitabine and cytarabine to treat cells derived from Ewing sarcoma patient samples and in advanced laboratory models, will effectively attack the Ewing sarcoma fusion protein and kill the tumour cells. If this research strategy is effective, the research group plans to design a clinical trial protocol for patients with Ewing sarcoma.

How could this project improve treatment options for Ewing sarcoma patients?

This project has been discussed with and endorsed by members of the Swedish Sarcoma Society, the largest sarcoma patient advocacy group in Sweden. If successful, it will provide the necessary preclinical evidence that can open the door for a new therapeutic option for Ewing sarcoma patients internationally

Sponsor Our Research Into Ewing Sarcoma